Latest Period
Q1 2026
Security Snapshot
Aldeyra Therapeutics, Inc. - Common Stock (ALDX) Institutional Ownership
CUSIP: 01438T106
13F Institutional Holders and Ownership History from Q2 2014 to Q2 2026
Institutions Reporting
126
Shares (Excl. Options)
37,247,515
Price
$1.69
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ALDX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 37,247,515
- Total 13F value
- $62,944,021
- Portfolio coverage rank
- 0%
- Share change
- -1,218,775
- Value change
- -$20,481,780
- Number of holders
- 126
- Shares outstanding
- 61,515,529
- SEC-reported price per share
- $2.13
- Insider filing price
- $2.13
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ALDX - Aldeyra Therapeutics, Inc. - Common Stock is tracked under CUSIP 01438T106.
- 126 institutions reported positions in Q1 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 126 to 18 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $62,944,021 to $3,019,834.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 126 institutions filings for Q1 2026.
Security key
01438T106
Latest holder period
Q1 2026
13F holders
126
13D/G owners
1
CIK / CUSIP context first
Open Q1 2026 holders
ALDX full holder history
Aldeyra Therapeutics, Inc. SEC filings
Aldeyra Therapeutics, Inc. company facts
Aldeyra Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 01438T106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
ALDX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 1.7% | $2,227,477 | 1,045,764 | BlackRock, Inc. | 30 Jun 2026 |
As of 31 Mar 2026, 126 institutional investors reported holding 37,247,515 shares of Aldeyra Therapeutics, Inc. - Common Stock (ALDX). This represents 61% of the company’s total 61,515,529 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
53%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 8.9% | 5,475,516 | 0% | 5.1% | $9,253,622 |
| BlackRock, Inc. | 6.1% | 3,763,887 | -2.2% | 0% | $6,360,969 |
| AQR CAPITAL MANAGEMENT LLC | 4.6% | 2,829,875 | +131% | 0% | $4,782,489 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 2,363,742 | 0% | 0% | $3,994,724 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 3.5% | 2,152,315 | +16% | 0.61% | $3,637,412 |
| 683 Capital Management, LLC | 2.4% | 1,500,000 | -2% | 0.24% | $2,534,999 |
| D. E. Shaw & Co., Inc. | 2.3% | 1,403,990 | -12% | 0% | $2,372,743 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,251,652 | +6.9% | 0% | $2,115,714 |
| STATE STREET CORP | 1.8% | 1,124,710 | +2.4% | 0% | $1,900,760 |
| MILLENNIUM MANAGEMENT LLC | 1.6% | 995,243 | +2159% | 0% | $1,681,961 |
| JANE STREET GROUP, LLC | 1.6% | 968,891 | +219% | 0% | $1,637,425 |
| ARDSLEY ADVISORY PARTNERS LP | 1.5% | 950,000 | -34% | 0.24% | $1,605,500 |
| RENAISSANCE TECHNOLOGIES LLC | 1.4% | 863,187 | +147% | 0% | $1,458,786 |
| ACADIAN ASSET MANAGEMENT LLC | 1.4% | 858,288 | -12% | 0% | $1,446,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3% | 807,778 | 0% | 0% | $1,365,145 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1.3% | 796,816 | -18% | 0.01% | $1,346,619 |
| Propel Bio Management, LLC | 1.2% | 730,606 | 0.78% | $1,234,724 | |
| DIMENSIONAL FUND ADVISORS LP | 1% | 624,170 | +1.9% | 0% | $1,054,812 |
| GOLDMAN SACHS GROUP INC | 0.88% | 543,146 | +78% | 0% | $917,917 |
| UBS Group AG | 0.87% | 537,569 | +462% | 0% | $908,492 |
| MORGAN STANLEY | 0.84% | 518,642 | -21% | 0% | $876,505 |
| NORTHERN TRUST CORP | 0.61% | 374,812 | -1.2% | 0% | $633,433 |
| VANGUARD FIDUCIARY TRUST CO | 0.55% | 338,621 | 0% | 0% | $572,269 |
| HRT FINANCIAL LP | 0.47% | 286,444 | 0% | $484,000 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.45% | 278,442 | +343% | 0% | $470,567 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 1,412,516 | $3,019,834 | -$80,306 | $2.13 | 18 |
| 2026 Q1 | 37,247,515 | $62,944,021 | -$20,481,780 | $1.69 | 126 |
| 2025 Q4 | 38,964,894 | $201,775,126 | -$2,038,386 | $5.18 | 135 |
| 2025 Q3 | 39,091,752 | $204,002,195 | +$26,942,734 | $5.22 | 129 |
| 2025 Q2 | 34,234,495 | $131,165,420 | -$14,803,182 | $3.83 | 121 |
| 2025 Q1 | 37,522,553 | $215,581,662 | +$3,357,660 | $5.75 | 124 |
| 2024 Q4 | 37,181,780 | $185,566,183 | +$2,534,433 | $4.99 | 117 |
| 2024 Q3 | 36,411,204 | $196,355,871 | +$6,362,230 | $5.39 | 111 |
| 2024 Q2 | 35,332,656 | $116,899,840 | -$329,270 | $3.31 | 103 |
| 2024 Q1 | 35,411,236 | $115,798,928 | +$808,753 | $3.27 | 101 |
| 2023 Q4 | 35,121,957 | $123,276,317 | -$16,780,776 | $3.51 | 103 |
| 2023 Q3 | 37,775,090 | $252,308,601 | -$9,900,512 | $6.68 | 120 |
| 2023 Q2 | 39,037,773 | $327,514,881 | +$24,184,461 | $8.39 | 119 |
| 2023 Q1 | 35,585,837 | $353,348,951 | +$15,344,761 | $9.93 | 107 |
| 2022 Q4 | 34,171,691 | $237,833,495 | -$18,830,170 | $6.96 | 93 |
| 2022 Q3 | 36,966,565 | $197,399,795 | +$1,459,079 | $5.34 | 85 |
| 2022 Q2 | 36,943,694 | $147,408,805 | -$7,357,330 | $3.99 | 88 |
| 2022 Q1 | 38,636,557 | $171,807,935 | +$10,287,580 | $4.44 | 102 |
| 2021 Q4 | 36,272,402 | $145,130,796 | -$44,887,818 | $4.00 | 110 |
| 2021 Q3 | 39,720,964 | $348,695,759 | -$60,891,971 | $8.78 | 114 |
| 2021 Q2 | 45,258,901 | $512,794,552 | +$153,473,538 | $11.33 | 130 |
| 2021 Q1 | 31,692,851 | $376,513,639 | +$122,609,589 | $11.88 | 107 |
| 2020 Q4 | 22,091,649 | $151,541,784 | -$10,169,396 | $6.86 | 95 |
| 2020 Q3 | 23,807,765 | $176,308,405 | +$68,333,848 | $7.41 | 84 |
| 2020 Q2 | 14,645,367 | $61,066,116 | -$6,590,170 | $4.17 | 79 |